



Supplementary Data:




S1: Angiotensin II increases the viability of human cerebrovascular endothelial cells (hCMECs). hCMECs were cultured and treated with different doses of AngII and their viability was assessed using MTT metabolism. AngII significantly increased the viability of hCMECs in all doses. * significantly different from ctrl; overall p=0.0001, F=18.36.

Ahmed Alhusban, Anna Kozak, Adviye Ergul, Susan C Fagan.
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator
Journal of pharmacology and experimental therapeutics




S2: AT1 expression is induced through AT2 stimulation. hCMECs were serum starved for 16 hours followed by treatment with either the AT2 agonist CGP-42112A (0.1 μ M) or vehicle and the expression of AT1 was quantified. Data presented as mean \pm SEM, n=3.

Ahmed Alhusban, Anna Kozak, Adviye Ergul, Susan C Fagan.
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator
Journal of pharmacology and experimental therapeutics



S3: AT1 blockade affects the expression of BDNF in wistar rats. Wistar rats were subjected to sham surgery and randomized to receive either saline or candesartan (1mg/kg) 3 hours after surgery. Candesartan significantly increased BDNF expression in both hemispheres as compared to the corresponding hemispheres in saline treated animals. p=0.04; n=4 per group.

Ahmed Alhusban, Anna Kozak, Adviye Ergul, Susan C Fagan.
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator
Journal of pharmacology and experimental therapeutics



S4: Blood pressure reduction with hydralazine did not affect BDNF expression. Spontaneously hypertensive rats were exposed to sham surgery and randomized to receive either saline or hydralazine (1mg/kg) 3 hours after surgery. Hydralazine treatment resulted in a trend toward increased BDNF expression in the brain; but this trend did not reach statistical significance level. n=4 per group.